BMY shares gained 5.6% after the company announced they are continuing the Phase 3 ADEPT-2 study for Cobenfy in Alzheimer's psychosis. It seems the market was pricing in a potential failure here. The company found execution irregularities at a small number of trial sites and decided to exclude that data. While this pushes the final readout from late this year to next year, the data monitoring committee recommended continuing the study and enrolling more patients.